Chloe Goossens
Erlangen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.
Journal: NPJ breast cancer
Published: November 29, 2025
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
Journal: Breast cancer research and treatment
Published: October 24, 2025
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.
Journal: International journal of cancer
Published: July 08, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 05, 2025
Adherence to digital pregnancy care - lessons learned from the SMART start feasibility study.
Journal: NPJ digital medicine
Published: May 08, 2025
Cross-sectional study on user requirements for developing a digital patient navigator app.
Journal: Digital health
Published: April 11, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.
Journal: Breast (Edinburgh, Scotland)
Published: December 23, 2024
Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality.
Journal: BMC immunology
Published: November 28, 2024
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.
Journal: Geburtshilfe und Frauenheilkunde
Published: November 20, 2024
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.
Journal: Geburtshilfe und Frauenheilkunde
Published: November 20, 2024
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
Journal: International journal of cancer
Published: September 20, 2024
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers.
Journal: Breast cancer research : BCR
Published: July 25, 2024
Last Updated: 09/26/2026